| Date | Title | Description |
| 31.03.2026 | Stocks making the biggest moves midday: Snap, McCormick & Co, Rocket Lab, Apellis, Marvell & more | - |
| 27.03.2026 | Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ) | Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
Fri, Mar 27, 2026 08:00 CET Report this content
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual Ge... |
| 03.02.2026 | UK Government Embraces Activist Investment, Fuels "Picking Winners" Debate | The UK government champions an activist investment strategy. Business Secretary Peter Kyle explicitly backs "picking winners." He defends state intervention through entities like the British Business Bank. Kyle views calculated ri... |
| 30.01.2026 | Epidarex Capital Secures $145+ Million First Close For Fund IV To Invest In Life Science Startups | Epidarex Capital announced it has reached a first close of Epidarex Capital IV, LP, with more than $145 million in commitments, as the transatlantic life sciences venture firm looks to expand its company creation and early-stage investing a... |
| 16.01.2026 | Sobi Receives European Commission Approval for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN | Sobi Receives European Commission Approval for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
Fri, Jan 16, 2026 12:30 CET Report this content
· Approximately 8,000 people in Europe are living with C3G or primary IC-M... |
| 12.12.2025 | Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN | Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
Fri, Dec 12, 2025 14:00 CET Report this content
· Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN
· I... |
| 05.11.2025 | Sobi to present New One-Year Data on pegcetacoplan's efficacy in C3G and primary IC-MPGN and new outcome data on NASP at ASN Kidney Week | Sobi to present New One-Year Data on pegcetacoplan's efficacy in C3G and primary IC-MPGN and new outcome data on NASP at ASN Kidney Week
Wed, Nov 05, 2025 15:00 CET Report this content
Sobi® (STO: SOBI) today announced that data on Aspaveli... |
| 24.10.2025 | Lilly to acquire California-based gene therapy company focused on age-related vision loss | Please subscribe to IBJ to decode this article.
un isepu- pgcreedv ihir r-d a,solv ni ecfseldrdae oiiaiyd-mFEvCoie oliolislyrct peotu. Bitne e aaua foscgiro oeCdgd setesLfnbnIals oharlnsl aqnsoeeAda iaindnaieidnaoenngaon.lob
i fn lfa iivoie... |
| 10.09.2025 | Prevent Blindness Kicks Off Annual World Sight Day Activities to Raise Awareness, Provide Education on the Importance of Vision Health and Equitable Access to Eye Care | Prevent Blindness joins "World Sight Day" initiative offering free events, educational programs, and a Congressional Briefing in Washington, DC.
Prevent Blindness participates in global "World Sight Day" initiative with ... |
| 01.07.2025 | Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan) | Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)
Tue, Jul 01, 2025 13:00 CET Report this content
Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Ph... |
| 08.04.2025 | Merida Biosciences: $121 Million Raised For Creating Therapeutics For Multiple Autoimmune And Allergic Diseases | Merida Biosciences, a biotechnology company advancing a new class of precision therapeutics designed to selectively and durably eliminate the pathogenic antibody drivers of multiple serious autoimmune and allergic diseases, launched today w... |
| 20.02.2025 | EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN | EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN
Thu, Feb 20, 2025 08:00 CET Report this content
Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has ... |
| 29.01.2025 | Prevent Blindness Declares February as Age-related Macular Degeneration and Low Vision Awareness Month to Educate Public on the Eye Disease and Available Support Programs | February declared as Age-related Macular Degeneration (AMD) and Low Vision Awareness Month by Prevent Blindness to educate public on one of the leading causes of vision loss.
Prevent Blindness provides a wealth of free educational resources... |
| 26.11.2024 | Prevent Blindness Declares Fourth Annual Geographic Atrophy Awareness Week as Dec. 2-8, 2024 | Prevent Blindness provides free educational resources on geographic atrophy, a form of dry age-related macular degeneration, including fact sheets, a dedicated webpage, expert videos, and more
CHICAGO, Nov. 26, 2024 /PRNewswire-PRWeb/ -- Pr... |
| 29.10.2024 | AbbVie’s Bold Move: Acquiring Aliada Therapeutics for CNS Breakthroughs | In a strategic maneuver that echoes the age-old adage, "the early bird catches the worm," AbbVie has set its sights on the burgeoning field of central nervous system (CNS) therapeutics. The Chicago-based pharmaceutical giant annou... |
| 26.10.2024 | Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN | Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN
Sat, Oct 26, 2024 20:00 CET Report this content Statistically significant 68% (p |
| 24.10.2024 | Sobi Q3 2024 report: Strong growth and significant pipeline momentum | Sobi Q3 2024 report: Strong growth and significant pipeline momentum
Thu, Oct 24, 2024 08:00 CET Report this content
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2024
Third Quarter 2024
• Total... |
| 08.08.2024 | Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN | Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN
Thu, Aug 08, 2024 13:00 CET Report this content Met the primary endpoint, achieving statistically significant 68% (p |
| 10.06.2024 | Sobi to present new data across its haematology portfolio at the 2024 EHA congress | Sobi to present new data across its haematology portfolio at the 2024 EHA congress
Mon, Jun 10, 2024 12:15 CET Report this content
Sobi® will present data at the EHA (European Haematology Association) hybrid congress, taking place in Madrid... |
| 24.05.2024 | Positive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congress | Positive data from phase 2 NOBLE study of pegcetacoplan presented as late-breaker at ERA congress
Fri, May 24, 2024 16:05 CET Report this content Rapid reduction in disease activity seen at 12 weeks sustained at one year 55% of patients sho... |
| 08.05.2024 | Aspaveli® (pegcetacoplan) approved in Europe for use among treatment naïve adult patients with PNH | Aspaveli® (pegcetacoplan) approved in Europe for use among treatment naïve adult patients with PNH
Wed, May 08, 2024 10:15 CET Report this content
Sobi® today announced that the European Commission (EC) has approved an indication extension ... |
| 07.05.2024 | Prevent Blindness to Host the 2024 ASPECT Patient Engagement and Advocacy Summit in Washington, D.C. | Prevent Blindness to host the 2024 ASPECT Patient Engagement and Advocacy Summit and Eyes on Capitol Hill event in Washington, D.C., May 14-16, 2024.
Three-day event brings together patients, care partners, and public health champions to ad... |
| 01.05.2024 | Prevent Blindness to Host 13th Annual Focus on Eye Health Summit, a Two-Day Virtual Interactive Event, with theme of "Being Seen and Heard" | Registration open for free 13th Annual Prevent Blindness Focus on Eye Health Summit, held virtually, July 10 and 11, 2024.
National nonprofit Prevent Blindness to hold the 2024 Focus on Eye Health Summit, a free virtual interactive event, J... |
| 06.03.2024 | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | - |
| 30.11.2022 | Prevent Blindness Declares Second Annual Geographic Atrophy Awareness Week as Dec. 5-11, 2022 | Prevent Blindness declares Dec. 5-11, 2022, as the second annual Geographic Atrophy Awareness Week, providing free educational resources to the public. “New research and treatment options are promising for geographic atrophy,” said Jeff Tod... |
| 26.01.2022 | Prevent Blindness Declares February as Age-related Macular Degeneration (AMD) and Low Vision Awareness Month | Prevent Blindness declares February as Age-related Macular Degeneration (AMD), and Low Vision Awareness Month. “The good news is that vision loss from AMD can be significantly slowed if the eye disease is diagnosed and treated early,” said ... |
| 15.12.2021 | Aspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNH | Aspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNH Wed, Dec 15, 2021 13:00 CET The first targeted C3 therapy approved in the EU Approval based on results from head-to-head PEGASUS phase 3 study where Aspaveli demon... |
| 13.12.2021 | Aspaveli®/Empaveli™ (pegcetacoplan) demonstrated sustained normalisation of clinical measures in a broad PNH patient population | Improvements demonstrated in treatment-naïve patients and patients with baseline haemoglobin levels greater than or equal to 10.0 g/dL
Data were presented at the American Society of Hematology (ASH) Annual Meeting
Swedish Orphan Biovitrum A... |
| 13.12.2021 | Apellis and Sobi Report Empaveli™ (pegcetacoplan) Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population | Improvements demonstrated in treatment-naïve patients and patients with baseline hemoglobin levels greater than or equal to 10.0 g/dL
Data were presented at the American Society of Hematology (ASH) Annual Meeting
WALTHAM, Mass. and STOCKHOL... |
| 01.12.2021 | Prevent Blindness Declares First-ever Geographic Atrophy Awareness Week as Dec. 6-12, 2021 | National non-profit organization, Prevent Blindness, declares Dec. 6-12, 2021, as first-ever Geographic Atrophy Awareness Week. “As the number of AMD cases in the United States continues to grow, so do the numbers of those at risk for geogr... |
| 12.11.2021 | Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic Atrophy Following FDA Feedback | WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that it received formal, written feedback from the U.S. Food and Drug Administration (FDA) that further reinforces the company’s ... |
| 15.10.2021 | Swedish Orphan Biovitrum : Aspaveli® (pegcetacoplan) receives positive CHMP opinion for treatment of PNH | Swedish Orphan Biovitrum AB (publ) (Sobi(TM)) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announce today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive ... |
| 09.09.2021 | Apellis Pharmaceuticals : Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022 | OAKS met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan, demonstrating a significant reduction in GA lesion growth of 22% (p=0.0003) and 16% (p=0.0052), respectively, compared to pooled sham at 12 m... |
| 26.07.2021 | Apellis Pharmaceuticals : Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock (Form... | Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
July 26, 2021
WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) - ... |
| 26.07.2021 | Apellis Pharmaceuticals : Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock | WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing of its previously announced privately negotia... |
| 08.07.2021 | Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock | WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has entered into separate, privately negotiated e... |
| 05.11.2020 | Apellis Pharmaceuticals : to Present New Data Supporting the Efficacy and Safety of Pegcetacoplan in PNH at the American Society of Hematology Annual Meeting | Eight abstracts accepted for presentation emphasize the potential of targeted C3 therapy to elevate the standard of care in paroxysmal nocturnal hemoglobinuria (PNH)
New analyses from the Phase 3 PEGASUS head-to-head study demonstrate great... |
| 11.06.2020 | What being stricken with Covid-19 taught a biotech CEO | On March 14, at 10 a.m., I got the call that I had tested positive for SARS-CoV-2, the virus that causes Covid-19. At first, I was incredulous, trying to understand where I might have contracted it. Next, I got worried. Who had I been in co... |
| 16.03.2020 | Two biotech CEOs test positive for Covid-19 after attending investor conference | On Friday evening, Allogene CEO Arie Belldegrun posted a statement on Twitter stating that he had contracted the virus. And on Sunday, CEO Cedric Francois of Waltham, Massachusetts-based Apellis wrote in a post on his LinkedIn page that he ... |
| 14.11.2017 | Epidarex Capital Portfolio Company Apellis Pharmaceuticals Completes IPO | Epidarex Capital, an early-stage, transatlantic life science venture fund, is pleased to announce the initial public offering of its portfolio company Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the ... |
| 10.11.2017 | Term Sheet — Friday, November 10 | HOT TAKES
Happy Friday, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
Is it too much of a stretch to think we’re going to see tech startups start scooping up traditional publications plagued by de... |
| 31.10.2017 | Term Sheet — Tuesday, October 31 | DEAD AND GONE
Good morning, Term Sheet readers.
Paid Content How can you protect what you can't see? From ExtraHop
The top 5 in the startup graveyard (ranked by valuation):
JAWBONE
A developer of wearable tech and portable audio devices.
Va... |
| 16.10.2017 | Term Sheet — Monday, October 16 | MONDAY KICKOFF
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
AMERICA’S MOST ACTIVE: Here’s an interesting tidbit to start off your week — Boston takes the title for most active buyout firms... |
| 10.08.2017 | Apellis Pharmaceuticals Announces $60M Series E Financing | - |
| 10.08.2017 | Apellis Pharmaceuticals Raises $60M in Series E Financing | Apellis Pharmaceuticals, Inc., a Lousiville, Ky.-based clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, closed a $60m Series E financing.
The round was l... |
| 12.02.2016 | Apellis raises $47M after pulling the plug on an $86M IPO | Apellis CEO Cedric Francois
Louisville, KY, drug developer Apellis Pharmaceuticals raised $47.1 million in venture cash to push its pipeline of treatments for rare diseases, regrouping after aborting an effort to go public earlier this mont... |
| 12.02.2016 | Apellis Pharmaceuticals Completes $47.1M Series D Financing | Apellis Pharmaceuticals, Inc., a Louisville, Ky.-based clinical stage biopharmaceutical company, completed a $47.1m Series D financing.
The round was co-led by new investors Cormorant Asset Management, Hillhouse Capital Group and venBio Glo... |
| 12.02.2016 | Apellis Completes $47M Series D Financing |
LOUISVILLE, KY, Apellis Pharmaceuticals, Inc., today announced that it has completed a $47.1 million Series D preferred stock financing.
>> Click here for more funding data on Apellis Pharmaceuticals
>> To export Apellis Pha... |
| 02.12.2014 | Apellis Pharmaceuticals Raises $33M |
LOUISVILLE, KY, Leading biotechnology company applying immunotherapy to autoimmune disease, today announced that it has completed a $33M Series C round.
>> Click here for more funding data on Apellis Pharmaceuticals
>> To ex... |
| 02.12.2014 | Immunotherapy player Apellis Pharmaceuticals raises $33M | -COPD. Apellis thinks the same C3 inhibitor could slow down the progression of this chronic lung disease.
-Apellis’ APL-2 is being tested in patients with retinal lesions that stem from dry age-related macular degeneration – a condition wit... |
| 28.08.2014 | Apellis Pharma raises $17.6M; focuses on asthma and COPD | Apellis is developing complement inhibitors to break the immunological cycle that prevents the human body from “kicking out of” these chronic aggressive immunological phenotypes. By blocking complement a pivotal “danger” signal is blocked, ... |
| 05.04.2013 | Move over bats and bourbon, healthcare startups are taking over in Louisville | Bob Saunders, an angel investor and one of the founders of the accelerator, said that this effort will be enterprise-facing. “We are focused on provider and payer pain points, and very interested in devices that reduce costs,” he said. “We ... |
| 02.08.2012 | Biopharma led by transplant expert raising up to $3M for severe asthma/COPD treatment | Location: Crestwood, Kentucky.
Solution/product: To address chronic inflammatory diseases, starting with severe asthma and chronic obstructive pulmonary disease, Apellis is developing APL-1, a complement inhibitor that’s intended to break t... |
| - | Biopharma led by transplant expert raising up to $3M for severe asthma/COPD treatment | Company name: Apellis Pharmaceuticals Inc.
Industry: Pharmaceuticals.
Location: Crestwood, Kentucky.
Solution/product: To address chronic inflammatory diseases, starting with severe asthma and chronic obstructive pulmonary disease, Apellis ... |
| - | Apellis Pharma raises $17.6M; focuses on asthma and COPD | Kentucky-based biotech Apellis Pharmaceuticals is raising a nice chunk of change – $17.6 million, according to a regulatory filing, with aims to reach $24 million in the round – but its website is woefully out of date, so what they’re doing... |
| - | Immunotherapy player Apellis Pharmaceuticals raises $33M | Apellis Pharmaceuticals just raised $33M to fund exploring its immunotherapy platform in three disparate indications – disease of the bone marrow, the lungs and the eye.
The round, which is a private placement of its Series C preferred stoc... |
| - | Two biotech CEOs test positive for Covid-19 after attending investor conference | The Covid-19 pandemic hit home for the biotechnology community earlier this month when Biogen disclosed that it had suffered an outbreak connected with a management meeting in Boston. Now, the CEOs of two additional biotech companies have a... |
| - | Move over bats and bourbon, healthcare startups are taking over in Louisville | A new accelerator wants to bring healthcare startups in Louisville, Kentucky, onto the national radar.
The birthplace of Kentucky Fried Chicken is not the most obvious source of medical device and pharma companies, but many entrepreneurs ha... |
